By Daniella Parra
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the appointment of Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a Consultant on intellectual property strategies.
The company said Dr. Holland brings over 20 years of experience in drug development, with expertise in solid-form technology and Dr. Lindeman, an experienced IP attorney, will advise on IP strategies for Conduit’s solid-form candidates.
“The appointment of Jo as Chief Scientific Officer underscores Conduit’s commitment to optimizing the value of our current intellectual property assets, while concurrently fostering the creation of new intellectual property,” said Dr. David Tapolczay, Chief Executive Officer. “Jo and Jeff have over 20 years of experience working together, and their new leadership roles will significantly enhance our intellectual property state, strategically positioning Conduit for future outlicensing opportunities.”
Contact:
